Mansoor Raza Mirza, MD

Articles

Dr Mirza on the Findings From Part 2 of the RUBY Trial in Endometrial Cancer

March 19th 2024

Mansoor Raza Mirza, MD, discusses findings from part 2 of the ENGOT-EN6-NSGO/GOG-3031/RUBY trial in primary advanced or recurrent endometrial cancer.

Dr Mirza on the Use of Dostarlimab/Chemotherapy By Molecular Class in Endometrial Cancer

October 27th 2023

Mansoor Raza Mirza, MD, discusses treatment outcomes with the use of dostarlimab plus chemotherapy in patients with primary advanced or recurrent endometrial cancer whose disease was mismatch repair deficient/microsatellite instability–high, TP53 mutated, or had no specific molecular profile.

Dr Mirza on the FDA Approval of Dostarlimab Plus Chemotherapy in dMMR/MSI-H Endometrial Cancer

July 31st 2023

Mansoor Raza Mirza, MD, discusses the significance of the FDA approval of dostarlimab in combination with chemotherapy in patients with mismatch repair–deficient or microsatellite instability–high endometrial cancer.

Dostarlimab in Combination with Chemotherapy for the Treatment of Primary Advanced or Recurrent Endometrial Cancer: A Placebo-Controlled Randomized Phase 3 Trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)

April 18th 2023

Mansoor R. Mirza, MD, reviews data from the phase 3 RUBY trial investigating dostarlimab in combination with carboplatin and paclitaxel for the treatment of primary advanced or recurrent endometrial cancer.

Dr Mirza on Dostarlimab Plus Chemotherapy in Endometrial Cancer

March 28th 2023

Mansoor Raza Mirza, MD, discusses findings from the phase 3 RUBY trial in patients with endometrial cancer.

Dr. Mirza on Safety Profile of Niraparib/Bevacizumab in Recurrent Ovarian Cancer

August 18th 2020

Mansoor Raza Mirza, MD,  discusses the safety ​profile of niraparib in combination with bevacizumab in platinum-sensitive recurrent ovarian cancer.

Dr. Mirza on the Implications of the NSGO-AVANOVA2/ENGOT-OV24 Trial in Ovarian Cancer

August 17th 2020

Mansoor Raza Mirza, MD, discusses the clinical implications of the final survival analysis of the phase 3 NSGO-AVANOVA2/ENGOT-OV24 trial in recurrent, platinum-sensitive ovarian cancer.

Dr. Mirza on Final Data of the NSGO-AVANOVA2/ENGOT-OV24 Trial in Ovarian Cancer

August 3rd 2020

Mansoor Raza Mirza, MD, discusses the final survival analysis of the phase 3 NSGO-AVANOVA2/ENGOT-OV24 trial in recurrent, platinum-sensitive ovarian cancer.

Dr. Mirza on the Evolving Treatment Landscape in Recurrent Ovarian Cancer

July 29th 2020

Mansoor Raza Mirza, MD, discusses the evolving treatment landscape in recurrent ovarian cancer.

Dr. Mirza on the ENGOT-OV42-NSGO/AVANOVA-Triplet Trial in Recurrent Ovarian Cancer

March 25th 2020

Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology in Rigshospitalet, Copenhagen University Hospital, discusses the planned phase III ENGOT-OV42-NSGO/AVANOVA trial in platinum-sensitive, recurrent ovarian cancer.

Dr. Mirza on Efficacy of Niraparib/Bevacizumab Combo in Recurrent Ovarian Cancer

September 4th 2019

Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology in Rigshospitalet, Copenhagen University Hospital, discusses results from the phase II NSGO-AVANOVA2/ENGOT-OV24 trial comparing niraparib with niraparib plus bevacizumab in patients with recurrent platinum-sensitive ovarian cancer.

Dr. Mirza on the Rationale for the AVANOVA Trial in Recurrent Ovarian Cancer

June 21st 2019

Mansoor Raza Mirza, MD, chief oncologist in the Department of Oncology in Rigshospitalet, Copenhagen University Hospital, Denmark, discusses the rationale for the AVANOVA study in patients with platinum-sensitive recurrent ovarian cancer.

Dr. Mirza on the Impact of PARP Inhibitors in Ovarian Cancer

April 2nd 2018

Mansoor Raza Mirza, MD, chief oncologist in the Department of Oncology in Rigshospitalet, Copenhagen University Hospital, Denmark, discusses the impact of PARP inhibitors in ovarian cancer.

Dr. Mirza Discusses Niraparib Dose Modifications for Patients With Low Body Weight

March 26th 2018

Mansoor Raza Mirza, MD, chief oncologist in the Department of Oncology in Rigshospitalet, Copenhagen University Hospital, Denmark, discusses a study of safety and dose modification for patients with low body weight receiving niraparib (Zejula) in the ENGOT-OV16/NOVA phase III trial during the 2018 Society of Gynecologic Oncology Annual Meeting.

Dr. Mirza on Niraparib Plus Bevacizumab Combo in Ovarian Cancer

September 10th 2017

Mansoor Raza Mirza, MD, chief oncologist in the Department of Oncology in Rigshospitalet, Copenhagen University Hospital, Denmark, and medical director of the Nordic Society of Gynecologic Oncology-Clinical Trial Unit, discusses phase I results of a trial exploring the combination of niraparib (Zejula) and bevacizumab (Avastin) in patients with platinum-sensitive epithelial ovarian cancer.

Dr. Mirza on Niraparib Efficacy Across Ovarian Cancer Subgroups

February 7th 2017

Mansoor Raza Mirza, MD, chief oncologist at Rigshospitalet, Copenhagen, Denmark, discusses the efficacy of niraparib as a treatment of patients with ovarian cancer.

Dr. Mirza on Impact of Niraparib in Ovarian Cancer

November 30th 2016

Mansoor Raza Mirza, MD, chief oncologist at Rigshospitalet, Copenhagen, Denmark, discusses niraparib in patients with platinum-sensitive recurrent ovarian cancer

Dr. Mirza on the Phase III NOVA Trial in Ovarian Cancer

October 9th 2016

Mansoor Raza Mirza, MD, chief oncologist, Rigshospitalet, Copenhagen University Hospital, discusses the results of the phase III NOVA trial during an interview at the 2016 ESMO Congress.